Clinical Drug Investigation

, Volume 29, Issue 7, pp 471–479 | Cite as

RETRACTED ​ARTICLE: Efficacy of Menatetrenone (Vitamin K2) against Non-Vertebral and Hip Fractures in Patients with Neurological Diseases

Meta-Analysis of Three Randomized, Controlled Trials
  • Jun Iwamoto
  • Hideo Matsumoto
  • Tsuyoshi Takeda
Original Research Article


Background and objective: Patients with neurological diseases such as Alzheimer’s disease, stroke and Parkinson’s disease have been reported to have vitamin K deficiency secondary to malnutrition, which increases the risk of non-vertebral and hip fractures. The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases.

Methods: A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed.

Results: Three RCTs of patients with Alzheimer’s disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson’s disease (n = 110, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment.

Conclusion: The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.


Bone Mineral Density Osteocalcin Menatetrenone Femoral Neck Width Respective Relative Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    The WHO Scientific Group. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003; 921: 86–109Google Scholar
  2. 2.
    Shiraki M, Shiraki Y, Aoki C, et al. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000; 15: 515–21CrossRefGoogle Scholar
  3. 3.
    Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am J Med 2004; 117: 549–55CrossRefGoogle Scholar
  4. 4.
    Iwamoto J, Takeda T, Ichimura S. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci 2001; 6: 487–92CrossRefGoogle Scholar
  5. 5.
    Iwamoto J, Matsumoto H, Takeda T. Efficacy of rise-dronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008; 24: 1379–84CrossRefGoogle Scholar
  6. 6.
    Sato Y, Kanoko T, Satoh K, et al. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med 2005; 165: 1737–42CrossRefGoogle Scholar
  7. 7.
    Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165: 1743–8CrossRefGoogle Scholar
  8. 8.
    Sato Y, Iwamoto J, Kanoko T, et al. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005; 64: 811–6CrossRefGoogle Scholar
  9. 9.
    Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007; 68: 911–5CrossRefGoogle Scholar
  10. 10.
    Sato Y, Iwamoto J, Kanoko T, et al. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord 2006; 21: 924–9CrossRefGoogle Scholar
  11. 11.
    Sato Y, Kanoko T, Satoh K, et al. Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer’s disease. Bone 2005; 36: 61–8CrossRefGoogle Scholar
  12. 12.
    Sato Y, Honda Y, Kaji M, et al. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency. Bone 2002; 31:114–8CrossRefGoogle Scholar
  13. 13.
    Sato Y, Honda Y, Kuno H, et al. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 1998; 23: 291–6CrossRefGoogle Scholar
  14. 14.
    Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166: 1256–61CrossRefGoogle Scholar
  15. 15.
    Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 4.2.4. [updated March 2005]. Chichester: John Wiley & Sons Ltd, 2005Google Scholar
  16. 16.
    Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. Clin Epidemiol 2005; 58: 882–93CrossRefGoogle Scholar
  17. 17.
    Orimo H, Fujita T, Onomura T, et al. Clinical evaluation of soft capsule menatetrenone (Ea-0167) in the treatment of osteoporosis: late phase II dose study [in Japanese]. J New Remedies Clinics 1992; 41: 1249–79Google Scholar
  18. 18.
    Hauschka PV, Lian JB, Cole DEC, et al. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 1989; 69: 990–1047CrossRefGoogle Scholar
  19. 19.
    Koshihara Y, Hoshi K. Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res 1997; 12: 431–8CrossRefGoogle Scholar
  20. 20.
    Shearer MJ. Vitamin K. Lancet 1995; 345: 229–34CrossRefGoogle Scholar
  21. 21.
    Vermeer C, Jie KSG, Knapen MHJ. Role of vitamin K in bone metabolism. Annu Rev Nutr 1995; 15: 1–22CrossRefGoogle Scholar
  22. 22.
    Tabb MM, Sun A, Zhou C, et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 2003; 278: 43919–27CrossRefGoogle Scholar
  23. 23.
    Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int 2007; 18: 963–72CrossRefGoogle Scholar
  24. 24.
    Booth SL, Tucker KL, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr 2000; 71: 1201–8CrossRefGoogle Scholar
  25. 25.
    Kaneki M, Hedges SJ, Hosoi T, et al. Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk. Nutrition 2001; 17: 315–21CrossRefGoogle Scholar
  26. 26.
    Szulc P, Chapuy MC, Meunier PJ, et al. Serum under-carboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993; 91: 1769–74CrossRefGoogle Scholar
  27. 27.
    Szulc P, Chapuy MC, Meunier PJ, et al. Serum under-carboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 1996; 18: 487–8CrossRefGoogle Scholar
  28. 28.
    Vergnaud P, Garnero P, Meunier PJ, et al. Under-carboxylated osteocalcin measured with a specific immuno-assay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997; 82: 719–24PubMedGoogle Scholar
  29. 29.
    Luukinen H, Käkönen SM, Pettersson K, et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 2000; 15: 2473–8CrossRefGoogle Scholar
  30. 30.
    Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 1999; 69: 74–9CrossRefGoogle Scholar
  31. 31.
    Epstein S. Is cortical bone hip? What determines cortical bone properties? Bone 2007; 41Suppl. 1: S3–8CrossRefGoogle Scholar
  32. 32.
    Orimo H, Fujita T, Onomura T, et al. Clinical evaluation of Ea-0167 (menatetrenone) in the treatment of osteoporosis: phase III double-blind multicenter comparative study with alfacalcidol [in Japanese]. Clin Eval 1992; 20: 45–100Google Scholar
  33. 33.
    Sato Y, Inose M, Higuchi I, et al. Changes in the supporting muscles of the fractured hip in elderly women. Bone 2002; 30: 325–30CrossRefGoogle Scholar
  34. 34.
    Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004; 291: 1999–2006CrossRefGoogle Scholar
  35. 35.
    Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293: 2257–64CrossRefGoogle Scholar
  36. 36.
    Hara K, Akiyama Y, Nakamura T, et al. The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone 1995; 16: 179–84CrossRefGoogle Scholar
  37. 37.
    Hara K, Akiyama Y, Tajima T, et al. Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro. J Bone Miner Res 1993; 8: 535–42CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Institute for Integrated Sports MedicineKeio University School of MedicineTokyoJapan

Personalised recommendations